FDA approves Lilly’s Symbyax for new use-WEB ONLY
Eli Lilly and Co. won U.S. approval for its drug Symbyax as a medicine for treatment-resistant depression, the company announced today. The U.S. Food and Drug Administration OK’d Symbyax as the first drug for the acute treatment of treatment-resistant depression. So-called TRD is depression that has not improved when treated by two other antidepressants. Symbyax […]